Matthew Galsky

Search results

• Non-chemo neoadjuvant combo explored in MIBC

  Matthew Galsky

  12/12/22

  1 item of Media coverage

  Press/Media

• Dr. Galsky explains results of pivotal adjuvant immunotherapy trials in urothelial cancer

  Matthew Galsky

  3/12/22

  1 item of Media coverage

  Press/Media

• Dr. Galsky explains the biomarker challenge with adjuvant immunotherapy in urothelial cancer

  Matthew Galsky

  2/12/22

  1 item of Media coverage

  Press/Media

• Current state of adjuvant immunotherapy for high-risk urothelial cancer

  Matthew Galsky

  1/12/22

  1 item of Media coverage

  Press/Media

• Prospective Data Establishing the Clinical Utility of Testing All Biomarkers in Advanced Bladder Cancer is Still Needed, Says Expert

  Matthew Galsky

  1/12/22

  1 item of Media coverage

  Press/Media

• Roundtable Discussion: Looking at the Role of Avelumab Maintenance in Metastatic Bladder Cancer

  Matthew Galsky

  29/11/22

  1 item of Media coverage

  Press/Media

• CMS covers ctDNA test for patients with MIBC

  Matthew Galsky,

  18/07/22

  1 item of Media coverage

  Press/Media

• Medicare Extends Coverage of Natera's Signatera™ MRD Test to Muscle Invasive Bladder Cancer

  Matthew Galsky,

  18/07/22

  98 items of Media coverage

  Press/Media

• Dr. Galsky on latest CheckMate-274 data for adjuvant nivolumab in bladder cancer

  Matthew Galsky,

  27/06/22

  1 item of Media coverage

  Press/Media

• Dr. Galsky on Initial Data From the CheckMate 274 Trial in Urothelial Cancer

  Matthew Galsky,

  1/06/22

  1 item of Media coverage

  Press/Media

• Immunotherapy after bladder cancer surgery shows excellent cancer-free survival rates

  Matthew Galsky,

  14/05/22 → 26/05/22

  9 items of Media coverage

  Press/Media

• Dr. Galsky on the Rationale of the CheckMate 274 Trial in Urothelial Carcinoma

  Matthew Galsky,

  24/05/22

  1 item of Media coverage

  Press/Media

• Immunotherapy With Nivolumab (Opdivo) Can Lower Recurrence When Bladder Cancer Spreads

  Matthew Galsky,

  16/05/22 → 20/05/22

  2 items of Media coverage

  Press/Media

• Immunotherapy Drug Can Lower Recurrence When Bladder Cancer Spreads

  Matthew Galsky,

  16/05/22 → 17/05/22

  137 items of Media coverage

  Press/Media

• Study: Immunotherapy Lowered Recurrence of Bladder Cancer That Had Spread

  Matthew Galsky,

  17/05/22

  2 items of Media coverage

  Press/Media

• Immunotherapy drug nivolumab may reduce risk of bladder cancer recurring

  Matthew Galsky,

  17/05/22

  1 item of Media coverage

  Press/Media

• AUA: Immunotherapy Aids Survival in Muscle-Invasive Bladder Cancer; Patients receiving nivolumab had an approximately 30 percent lower likelihood of developing cancer recurrence versus placebo.

  Matthew Galsky,

  17/05/22

  1 item of Media coverage

  Press/Media

• AUA: Immunotherapy Aids Survival in Muscle-Invasive Bladder Cancer

  Matthew Galsky,

  17/05/22

  81 items of Media coverage

  Press/Media

• Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival

  Matthew Galsky,

  16/05/22

  1 item of Media coverage

  Press/Media

• Urologists explore role of robotics, equity, exercise and medicine on bladder cancer

  Matthew Galsky

  16/05/22

  1 item of Media coverage

  Press/Media

• Immunotherapy helps reduce cancer recurrence

  Matthew Galsky,

  16/05/22

  1 item of Media coverage

  Press/Media

• Urologists Explore The Role Of Robotics, Equity, Exercise And Medicine On Bladder Cancer'

  Matthew Galsky,

  14/05/22 → 16/05/22

  67 items of Media coverage

  Press/Media

• Immunotherapy Drug Can Lower Recurrence When Bladder Cancer Spreads.

  Matthew Galsky,

  16/05/22

  1 item of Media coverage

  Press/Media

• Bladder Cancer: Immunotherapy After Surgery Improves Cancer-Free Survival Rates

  Matthew Galsky,

  15/05/22

  1 item of Media coverage

  Press/Media

• Dr. Galsky on Updated CheckMate 274 Data With Adjuvant Nivolumab in Urothelial Carcinoma

  Matthew Galsky,

  15/05/22

  1 item of Media coverage

  Press/Media